Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 Journal of Pharmaceutical Innovation Springer Nature Link The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Is BPC 157 Legal? Understanding Its Status and Implications FDA takes first step in possible reversal of ban on some peptides The Washington Post FDA to Convene Pharmacy Compounding Advisory Committee in July